ZA966552B - Endothelin receptor antagonists. - Google Patents
Endothelin receptor antagonists.Info
- Publication number
- ZA966552B ZA966552B ZA9606552A ZA966552A ZA966552B ZA 966552 B ZA966552 B ZA 966552B ZA 9606552 A ZA9606552 A ZA 9606552A ZA 966552 A ZA966552 A ZA 966552A ZA 966552 B ZA966552 B ZA 966552B
- Authority
- ZA
- South Africa
- Prior art keywords
- receptor antagonists
- endothelin receptor
- endothelin
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19528418A DE19528418A1 (de) | 1995-08-02 | 1995-08-02 | Endothelin-Rezeptor-Antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA966552B true ZA966552B (en) | 1997-02-18 |
Family
ID=7768528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9606552A ZA966552B (en) | 1995-08-02 | 1996-08-01 | Endothelin receptor antagonists. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5731321A (xx) |
| EP (1) | EP0757039A1 (xx) |
| JP (1) | JPH0940649A (xx) |
| KR (1) | KR970010746A (xx) |
| AR (1) | AR004675A1 (xx) |
| AU (1) | AU705959B2 (xx) |
| BR (1) | BR9603252A (xx) |
| CA (1) | CA2182469A1 (xx) |
| CZ (1) | CZ224096A3 (xx) |
| DE (1) | DE19528418A1 (xx) |
| HU (1) | HUP9602127A1 (xx) |
| MX (1) | MX9603199A (xx) |
| NO (1) | NO963213L (xx) |
| PL (1) | PL315479A1 (xx) |
| SK (1) | SK100296A3 (xx) |
| ZA (1) | ZA966552B (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0815870A3 (en) * | 1996-06-27 | 2000-05-03 | Takeda Chemical Industries, Ltd. | Composition for prohylaxis or treatment of cerebral infarction |
| DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| US7825131B2 (en) * | 2003-09-23 | 2010-11-02 | Merck Sharp & Dohme Corp. | Quinoline potassium channel inhibitors |
| US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| CA2696430C (en) * | 2007-08-16 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Quinazolinedione chymase inhibitors |
| ATE541841T1 (de) * | 2007-11-15 | 2012-02-15 | Boehringer Ingelheim Int | Inhibitoren der replikation des human immunodeficiency virus |
| EP2220046B1 (en) * | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| GB9115153D0 (en) * | 1991-07-12 | 1991-08-28 | Patel Bipin C M | Sol-gel composition for producing glassy coatings |
| DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
| US5565472A (en) * | 1992-12-21 | 1996-10-15 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents |
| ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| DK0617001T3 (da) * | 1993-03-19 | 2000-04-17 | Merck & Co Inc | Phenoxyphenyleddikesyrederivater |
| JPH06340658A (ja) * | 1993-04-08 | 1994-12-13 | Kyowa Hakko Kogyo Co Ltd | ベンゾイミダゾール誘導体 |
| EP0723449A1 (en) * | 1993-08-06 | 1996-07-31 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| DE4341663A1 (de) * | 1993-12-07 | 1995-06-08 | Basf Ag | Anellierte 2-Oxopiperazine, ihre Herstellung und Verwendung |
-
1995
- 1995-08-02 DE DE19528418A patent/DE19528418A1/de not_active Withdrawn
-
1996
- 1996-07-29 CZ CZ962240A patent/CZ224096A3/cs unknown
- 1996-07-29 AU AU60792/96A patent/AU705959B2/en not_active Ceased
- 1996-07-31 CA CA002182469A patent/CA2182469A1/en not_active Abandoned
- 1996-07-31 EP EP96112347A patent/EP0757039A1/de not_active Withdrawn
- 1996-07-31 SK SK1002-96A patent/SK100296A3/sk unknown
- 1996-08-01 BR BR9603252A patent/BR9603252A/pt not_active Application Discontinuation
- 1996-08-01 ZA ZA9606552A patent/ZA966552B/xx unknown
- 1996-08-01 US US08/691,148 patent/US5731321A/en not_active Expired - Fee Related
- 1996-08-01 HU HU9602127A patent/HUP9602127A1/hu unknown
- 1996-08-01 KR KR1019960032224A patent/KR970010746A/ko not_active Application Discontinuation
- 1996-08-01 NO NO963213A patent/NO963213L/no unknown
- 1996-08-01 PL PL96315479A patent/PL315479A1/xx unknown
- 1996-08-02 JP JP8219113A patent/JPH0940649A/ja active Pending
- 1996-08-02 MX MX9603199A patent/MX9603199A/es unknown
- 1996-08-02 AR ARP960103850A patent/AR004675A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR004675A1 (es) | 1999-03-10 |
| MX9603199A (es) | 1997-07-31 |
| NO963213D0 (no) | 1996-08-01 |
| SK100296A3 (en) | 1997-03-05 |
| NO963213L (no) | 1997-02-03 |
| AU705959B2 (en) | 1999-06-03 |
| AU6079296A (en) | 1997-02-06 |
| EP0757039A1 (de) | 1997-02-05 |
| PL315479A1 (en) | 1997-02-03 |
| CZ224096A3 (en) | 1997-02-12 |
| DE19528418A1 (de) | 1997-02-06 |
| KR970010746A (ko) | 1997-03-27 |
| HU9602127D0 (en) | 1996-09-30 |
| CA2182469A1 (en) | 1997-02-03 |
| JPH0940649A (ja) | 1997-02-10 |
| US5731321A (en) | 1998-03-24 |
| HUP9602127A1 (hu) | 1998-05-28 |
| BR9603252A (pt) | 1998-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA969775B (en) | Endothelin receptor antagonists. | |
| EP0676959A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS. | |
| ZA9610854B (en) | Vitronectin receptor antagonists. | |
| ZA9610859B (en) | Vitronectin receptor antagonists. | |
| EP0763035A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| ZA9610855B (en) | Vitronectin receptor antagonists. | |
| AU4803996A (en) | Endothelin receptor antagonists | |
| IL111431A0 (en) | Endothelin receptor antagonists | |
| EP0612244A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS. | |
| ZA985678B (en) | 1-amino-alkylcyclohexane NMDA receptor antagonists. | |
| SG49667A1 (en) | Endothelin receptor antagonists | |
| HU9600256D0 (en) | Substituted diphenyl-sulfonamides, antagonists of endothelin | |
| EP0766684A4 (en) | ENDOTHELINE RECEPTOR ANTAGONISTS | |
| HUP9902817A3 (en) | Endothelin receptor antagonists | |
| HU9602054D0 (en) | Endothelin receptor antagonists | |
| EP0854721A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| ZA966552B (en) | Endothelin receptor antagonists. | |
| ZA971184B (en) | Endothelin antagonists. | |
| EP0768878A4 (en) | ENDOTHELINE RECEPTOR ANTAGONISTS | |
| EP0841926A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| AU6200296A (en) | Endothelin receptor antagonists | |
| EP0841916A4 (en) | ENDOTHELINE RECEPTOR ANTAGONISTS | |
| AU6826698A (en) | Endothelin receptor antagonists | |
| ZA965754B (en) | Butenolide endothelin antagonists | |
| EP0868180A4 (en) | ENDOTHELINM RECEPTOR ANTOGONISTS |